Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6649-6657

  Kenny, Laura M ^a   Contractor, Kaiyumars B ^a   Stebbing, Justin ^a   Al Nahhas, Adil ^b   Palmieri, Carlo ^a   Shousha, Sami ^b   Coombes, R Charles ^a   Aboagye, Eric O ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CAPECITABINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; WATER O 15;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG SELECTIVITY; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DETECTION;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; FLUOROURACIL; HUMANS; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; THYMIDYLATE SYNTHASE;

EID: 70350719346     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1213     Document Type: Article

References (30)

1. Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Novel opportunities for thymidylate metabolism as a therapeutic target. Mol Cancer Ther 2008;7: 3029-3037
2. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12: 2035-2042 (Pubitemid 24356018)
3. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352: 476-487
4. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 1991;51:2346-2352
5. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
6. Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004;31:6-13. (Pubitemid 39370104)
7. Tominaga T, Toi M, Ohashi Y, Abe O. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 2002;3:55-64. (Pubitemid 34546073)
8. Jackman AL, Theti DS, Gibbs DD. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 2004;56:1111-1125 (Pubitemid 38496511)
9. Jansen G, Schornagel JH, Westerhof GR, Rijksen G, Newell DR, Jackman AL. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res 1990;50:7544-7548
10. Smith PG, Marshman E, Calvert AH, Newell DR, Curtin NJ. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. Semin Oncol 1999;26:63-67 (Pubitemid 29218030)
11. Jones TR, Calvert AH, Jackman AL, Brown SJ, Jones M, Harrap KR. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981;17:11-19
12. Ford HE, Mitchell F, Cunningham D, et al. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res 2002;8:103-109 (Pubitemid 34101464)
13. Rafi I, Boddy AV, Calvete JA, et al. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 1998;16:1131-1141 (Pubitemid 28108750)
14. Wells P, Aboagye E, Gunn RN, et al. 2-[11C] thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003;95:675-682 (Pubitemid 36603724)
15. Yau K, Price P, Pillai RG, Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 2006; 33:981-987 (Pubitemid 44215663)
16. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006;66: 8558-8564 (Pubitemid 44449169)
17. Pillai RG, Forster M, Perumal M, et al. Imaging pharmacodynamics of the α-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 2008;68:3827-3834
18. Direcks WG, Berndsen SC, Proost N, et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008;99:481-487
19. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-1347
20. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidinepositron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005; 65:10104-10112 (Pubitemid 41541493)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
22. Cleij MC, Brady F, Ell PJ, Pike VW, Luthra SK. An improved synthesis of 3′-deoxy-3′[18F] fluorothymdiine ([18F]FLT) and the fate of the precursor, 2,3′-anydro-5′-O-(4,4′-dimethoxytrityl)-thymidine. J Labelled Comp Radiopharm 2001; 44:S871-3.
23. Budman DR. Capecitabine. Invest New Drugs 2000;18:355-363
24. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006;11:325-335
25. Kety S. The theory and applications of exchange of inert gas at the lungs and tissues. Pharmacol Res 1951;3:1-41.
26. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-2830 (Pubitemid 46621829)
27. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13:15-23. (Pubitemid 23016599)
28. Aboagye EO, Price PM. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003;21: 169-181 (Pubitemid 36859317)
29. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-338 (Pubitemid 37328853)
30. Shields AF, Briston DA, Chandupatla S, et al. A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 2005;32:1269-1275 (Pubitemid 41598717)